S J Goldie1, M C Weinstein, K M Kuntz, K A Freedberg. 1. Center for Risk Analysis, Department of Health Policy and Management, Harvard University School of Public Health, Boston, Massachusetts 02115-5924, USA. sgoldie@hsph.harvard.edu
Abstract
BACKGROUND: Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain. OBJECTIVE: To assess the net health consequences, costs, and cost-effectiveness of various screening strategies for cervical neoplasia and cancer in HIV-infected women. DESIGN: A cost-effectiveness analysis from a societal perspective done by using a state-transition Markov model. Values for incidence, progression, and regression of cervical neoplasia; efficacy of screening and treatment; progression of HIV disease; mortality from HIV infection and cancer; quality of life; and costs were obtained from the literature. SETTING: Simulated clinical practice in the United States. PATIENTS: HIV-infected women representative of the U.S. population. INTERVENTION: Six main screening strategies--no screening, annual Papanicolaou smears, annual Papanicolaou smears after two negative smears obtained 6 months apart (recommended by the Centers for Disease Control and Prevention), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy--were considered. MEASUREMENTS: Quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness. RESULTS: Annual Papanicolaou smear screening resulted in a 2.1-month gain in quality-adjusted life expectancy for an incremental cost of $12,800 per QALY saved. Annual Papanicolaou smear screening after two negative smears obtained 6 months apart provided an additional 0.04 QALYs at a cost of $14,800 per QALY saved. Semiannual Papanicolaou smear screening provided a further 0.17 QALYs at a cost of $27,600 per QALY saved. Annual colposcopy cost more but provided no additional benefit compared with that given by semiannual Papanicolaou smear screening, and semiannual colposcopy exceeded $375,000 per QALY saved. Results were most sensitive to the rate of progression of neoplasia to invasive cancer. CONCLUSIONS: In HIV-infected women, cervical cancer screening with annual Papanicolaou smears after two negative smears obtained 6 months apart offers quality-adjusted life expectancy benefits at a cost comparable to that of other clinical preventive interventions.
BACKGROUND:Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain. OBJECTIVE: To assess the net health consequences, costs, and cost-effectiveness of various screening strategies for cervical neoplasia and cancer in HIV-infectedwomen. DESIGN: A cost-effectiveness analysis from a societal perspective done by using a state-transition Markov model. Values for incidence, progression, and regression of cervical neoplasia; efficacy of screening and treatment; progression of HIV disease; mortality from HIV infection and cancer; quality of life; and costs were obtained from the literature. SETTING: Simulated clinical practice in the United States. PATIENTS: HIV-infectedwomen representative of the U.S. population. INTERVENTION: Six main screening strategies--no screening, annual Papanicolaou smears, annual Papanicolaou smears after two negative smears obtained 6 months apart (recommended by the Centers for Disease Control and Prevention), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy--were considered. MEASUREMENTS: Quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness. RESULTS: Annual Papanicolaou smear screening resulted in a 2.1-month gain in quality-adjusted life expectancy for an incremental cost of $12,800 per QALY saved. Annual Papanicolaou smear screening after two negative smears obtained 6 months apart provided an additional 0.04 QALYs at a cost of $14,800 per QALY saved. Semiannual Papanicolaou smear screening provided a further 0.17 QALYs at a cost of $27,600 per QALY saved. Annual colposcopy cost more but provided no additional benefit compared with that given by semiannual Papanicolaou smear screening, and semiannual colposcopy exceeded $375,000 per QALY saved. Results were most sensitive to the rate of progression of neoplasia to invasive cancer. CONCLUSIONS: In HIV-infectedwomen, cervical cancer screening with annual Papanicolaou smears after two negative smears obtained 6 months apart offers quality-adjusted life expectancy benefits at a cost comparable to that of other clinical preventive interventions.
Authors: Tazio Vanni; Jonathan Karnon; Jason Madan; Richard G White; W John Edmunds; Anna M Foss; Rosa Legood Journal: Pharmacoeconomics Date: 2011-01 Impact factor: 4.981
Authors: Groesbeck P Parham; Vikrant V Sahasrabuddhe; Mulindi H Mwanahamuntu; Bryan E Shepherd; Michael L Hicks; Elizabeth M Stringer; Sten H Vermund Journal: Gynecol Oncol Date: 2006-07-27 Impact factor: 5.482
Authors: Mucahit Cevik; Mehmet Ali Ergun; Natasha K Stout; Amy Trentham-Dietz; Mark Craven; Oguzhan Alagoz Journal: Med Decis Making Date: 2015-10-15 Impact factor: 2.583